| abstract |
The present invention relates to the design of customized treatments for a subject having breast cancer based on the c-MAF expression level and menopausal status of the subject. In some embodiments, the customized treatment includes an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid. In one aspect, an in vitro method for designing a customized treatment for a subject with breast cancer is provided, the method comprising i) c-MAF gene expression level, copy number, amplification or gain in a sample of the subject. And ii) comparing the expression level, copy number, amplification or gain obtained in i) to a reference value. |